Sagarsoft™, Baxter’s ™ Market Penetration Strategy & the Hemophilia Market

Sagarsoft™, Baxter’s ™ Market Penetration Strategy & the Hemophilia Market

Quick Facts

Domain: Web Application
Client Profile:
Technology: ASP.Net, AJAX, MS SQL Server, JQuery, Javascript, Third Part Tools
Execution & Delivery: Agile; Offshore Model

The Sagarsoft™ Advantage
Our mature team and processes drastically cut down on development time (50-70%) even during first encounter with new technologies.

Transparent decision making with agreed upon milestones guarantee an accurate, high performance, intuitive application portfolio.

Download Case study in PDF Format Download PDF

Sagarsoft’s™ Contribution Towards Helping Baxter™ Retain Position and Penetrate Further into One of the Biggest & Fastest Growing Specialty Segment – Hemophilia

The Hemophilia market is expected to grow at an average rate of 5.9% through 2017, expanding to $11.4 billion in value by 2016 (Morningstar Healthcare Observer, Jan 2013 report). New entrants continue to seep into this Baxter™, Bayer™ and Pfizer™ dominated recombinant protein market.

In a competitive scenario, Baxter™ turned to Core Access™ to help sketch a strategy that would supposedly help them retain market share and penetrate further into the biggest Hemophilia market – Hemophilia A.

In order to address this challenge, our team at Sagarsoft™, in consultation with Core Access™ created a robust, rapid computing graphical statistical application to help unravel the changing face of Hemophilia pharmaceutical market data.

HemoMAP™ Solution Brief

  • HempMAP™ is the Hemophilia Market Access Planner designed exclusively for Baxter™, designed to gain insights into market dynamics by brand and by payer profiles.
  • The application is capable of tracking Baxter™ and competition data spanning the portion of recombinant protein market targeted to Hemophilia treatment.
  • Data can be filtered to individual brand level, pertaining to relevant Hemophilia Factors, for applying filter criteria.

Business Impact

The Hemophilia market for recombinant factor proteins is growing at a rapid pace. Presently, new mature forms of Factor VIII and IX for Hemophilia are gaining market position. In this competitive scenario, Baxter™ can afford to dominate the segment strictly through a scientifically planned market access strategy – an intuitive market data scan that was planned by Core Access™ and executed computationally by Sagarsoft™.

Team & Process Maturity at Sagarsoft™

  • Sagarsoft™ expertise with Microsoft™ technologies for web applications helped render complex graphs with the help of external controls. Our competent resources, trained in diverse technology platforms gracefully leverage technology benefits from third party components to take advantage of performance gains in specialized areas.
  • Industry compliant best practices with respect to code reuse and inter component compatibility helped us generate HempMAP™ in less than 30 – 50% of usual time.
  • Our mature development process promises total transparency to client. We engage the best talent in the industry and execute a milestone dependent project plan. Our support applications for critical pharmaceutical marketing are promising in terms of performance, accuracy and intuitiveness.
CoreAccess Hemomap Web
CoreAccess Hemomap Web

Leave a Comment

Comment (required)

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>